Resources
9 Results (showing 1 - 9)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 3/30/2021 (updated 4/5/2024)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 1/19/2022 (updated 3/26/2024)
With the worst opioid overdose death crisis in the United States history, urgent new approaches to assist people who use drugs onto medication for opioid use disorder are necessary. In this commentary, addiction medicine clinicians and drug user union representatives align to argue that conventional ways of buprenorphine initiation that require periods of withdrawal must be augmented with additional novel approaches to initiation.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.
Posted 6/22/2023 (updated 3/28/2024)
The Buncombe Bridge to Care (BB2C): Post-Overdose Buprenorphine Field Initiation Program Toolkit was developed by Buncombe County Emergency Services Community Paramedicine and UNC Health Sciences at Mountain Area Health Education Center (MAHEC). This toolkit describes the project and protocols utilized. It is not intended to be a comprehensive guide or manual, but instead to inspire communities to increase access to lifesaving medication for the marginalized community of people who use drugs.